Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy
Small · 2024
DOI: 10.1002/smll.202400977 ↗Kurz gefasst
Fachartikel in der Zeitschrift Small, 2024. Verfasst von Feiqi Liu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital of Jilin Universit…. Hauptthemen laut MEDLINE: Breast Neoplasms, Ado-Trastuzumab Emtansine, Nanoparticles, Trastuzumab. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Department of Human Resource and Social Security of Jilin Province.
Abstract (Originalsprache)
Trastuzumab emtansine (T‐DM1), an antibody‐drug conjugate, revolutionizes breast cancer therapy by specifically delivering DM1 to human epidermal growth factor receptor 2 (HER2) overexpressing tumor cells, effectively inhibiting cell division and proliferation. While T‐DM1 demonstrates superior efficacy and tolerability, T‐DM1‐induced thrombocytopenia remains a significant adverse event leading to treatment discontinuation. To address this issue, the study investigates the feasibility of using poly(lactic‐co‐glycolic acid) (PLGA) nanoparticles as a delivery vehicle to conjugate T‐DM1, aiming to alleviate T‐DM1‐induced thrombocytopenia. The T‐DM1‐conjugated PLGA nanoparticles (NPs‐T‐DM1) reduce binding to megakaryocytes without compromising the targeting ability for HER2. Administration of NPs‐T‐DM1 not only significantly inhibits tumor growth but also reduces damage to megakaryocytes, inhibits T‐DM1‐induced thrombocytopenia, and remarkably improves the safety of antibody‐conjugated drugs. This work presents a promising strategy to enhance the safety and efficacy of T‐DM1 in antitumor therapy, offering significant potential for advancing clinical application in HER2‐positive breast cancer patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Organ Regeneration and Transplantation of the Ministry of Education, Institute of Immunology, The First Hospital of Jilin University, Changchun, Jilin, 130000, China.
- Department of Critical Care Medicine, The First Hospital of Jilin University, Changchun, Jilin, 130000, China.
- International Center of Future Science, Jilin University, Changchun, Jilin, 130000, China.
- National-local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin, 130000, China.
- Department of Oncology, Shandong Provincial Hospital, Jinan, Shandong, 250000, China.
- Department of Hepatobiliary and Pancreatic Surgery, General Surgery Center, The First Hospital of Jilin University, Changchun, Jilin, 130000, China.
ORCID-Profile: Feiqi Liu, Jianji Ke, Yanqiu Song, Tianmeng Sun
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Department of Human Resource and Social Security of Jilin Province
- Bethune Medical Department of Jilin University
- Youth Development Fund of the First Hospital of Jilin University
Zitieren
APA
Liu, F., Mao, K., Chen, H., Cong, X., Tan, H., Xin, Y., Wang, X., Ke, J., Song, Y., Yang, Y. G., & Sun, T. (2024). Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy. Small. https://doi.org/10.1002/smll.202400977
Vancouver
Liu F, Mao K, Chen H, Cong X, Tan H, Xin Y, et al. Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy. Small. 2024. doi:10.1002/smll.202400977
BibTeX
@article{Liu2024,
author = {Liu, Feiqi and Mao, Kuirong and Chen, Hongmei and Cong, Xiuxiu and Tan, Huizhu and Xin, Yanbao and Wang, Xin and Ke, Jianji and Song, Yanqiu and Yang, Yong-Guang and Sun, Tianmeng},
title = {Enhancing the Safety and Efficacy of Trastuzumab Emtansine (T‐DM1) Through Nano‐Delivery System in Breast Cancer Therapy},
journal = {Small},
year = {2024},
doi = {10.1002/smll.202400977}
}
EUVIMED